Pharmacokinetics of the New Hepatitis C Virus NS3 Protease Inhibitor Narlaprevir following Single-Dose Use with or without Ritonavir in Patients with Liver Cirrhosis

In this study we sought to evaluate narlaprevir (NVR) pharmacokinetics (PK) after a single dose with or without ritonavir (RTV) in cirrhotic versus healthy subjects. NVR at 200 mg was administered to 8 healthy and 8 cirrhotic subjects, and NVR at 100 mg with RTV at 100 mg was administered to 8 healt...

Descripción completa

Detalles Bibliográficos
Autores principales: Isakov, V., Koloda, D., Tikhonova, N., Kikalishvili, T., Krasavina, E., Lekishvili, K., Malaya, I., Ryska, M., Samsonov, M., Tolkacheva, V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2016
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5118988/
https://www.ncbi.nlm.nih.gov/pubmed/27645244
http://dx.doi.org/10.1128/AAC.01044-16

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5118988/
https://www.ncbi.nlm.nih.gov/pubmed/27645244
http://dx.doi.org/10.1128/AAC.01044-16

Ejemplares similares